Navigation Links
BellBrook Labs Launches Second Generation Transcreener EPIGEN Methyltransferase Assay to Acclerate Epigenetic Drug Discovery
Date:8/15/2013

Madison, WI (PRWEB) August 15, 2013

Methyltransferases are key players in epigenetic control of gene expression and have become the targets of intensive public and private drug discovery efforts. To accelerate these efforts, BellBrook developed the Transcreener EPIGEN Methyltransferase Assay, a fluorescent SAH detection assay with the sensitivity needed to detect any methyltransferase at physiological SAM concentrations, and the robustness required for industrial HTS. Since its introduction in 2011, the EPIGEN assay has been validated on all of the major instrument platforms and adopted by industrial and academic laboratories worldwide. Now, in response to customer feedback, we have reduced the number of components and simplified the protocol. The performance and response of the simplified assay is identical to the original kit; it contains pre-mixed detection components, so assay set-up is simpler and results are more reproducible.

By utilizing its expertise in HTS assay development, the BellBrook team is able to offer universal, fluorescence based detection of any methyltransferase enzyme that uses SAM as a methyl donor. This approach avoids the complexities and difficulties of detecting specific methylated products. The EPIGEN assay relies on enzymatic conversion of SAH to AMP, which is then detected using the Transcreener® AMP/GMP Assay. It provides robust activity measurements even with very low levels of SAM, while still offering the outstanding deck and signal stability of BellBrook’s Transcreener® Assays. Similar EPIGEN assays are being developed to screen additional epigenetic enzymes, including Histone Acetyltransferases (HATs).

About BellBrook Labs
BellBrook Labs is dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions for enzymes and phenotypic assays. The company’s Transcreener® HTS enzyme assays, used by all of the major pharmaceutical companies, make it easy to screen thousands of different enzymes, including validated targets like kinases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. The iuvo™ Microconduit Array technology and assay screening service is a line of unique microscale devices for miniaturization and automation of advanced cell models that are more representative of human physiology.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11024850.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. BellBrook Labs and Tecan Offer Webinar on Screening Epigenetic Targets
2. BellBrook Labs Launches Four New Turn-Key Methyltransferase Assay Kits
3. BellBrook Labs and BMG Labtech to Offer Webinar on Integrated Platform for Screening Kinases and Methyltransferases
4. BellBrook Labs Strengthens Ties with Cambio for Distribution of Transcreener HTS Assays in the UK
5. BioStorage Technologies Launches INTEGRITY Study to Measure Effect of Time, Temperature and Preparation Methods on DNA and RNA Samples
6. 23andMe Launches First National TV Campaign
7. Pearly Whites Laser Dentistry Launches Ground Breaking Cavity Prevention Program that Can Lower Decay Rates by 74%
8. Dr. Gray Bailey Launches Ground Breaking Cavity Prevention Program That Can Lower Tooth Decay Rates by 74%
9. ASAE Launches New Book Guiding Association Professionals on How to Use Research for Results
10. Pure Transplant Solutions Launches Crowdfunding Campaign for Its Novel Technology Poised to Change the Future of Organ Transplantation
11. SoundConnect Launches Innovative Partner Incentive Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Nova Oculus Partners has forged ... medical device for the treatment of Age-Related Macular Degeneration. , The company’s chief ... regulatory consultancy that helps companies like ours secure government approvals for their medical ...
(Date:1/21/2017)... LEAWOOD, Kan. , Jan. 20, 2017 ... pet therapeutics company focused on the licensing, development and ... Animal Pharm,s Best Company in ... was granted the award based on the ... ® (grapiprant tablets), ENTYCE ® (capromorelin oral ...
(Date:1/20/2017)... , January 20, 2017 ... market conditions have influenced the most recent performances of ... Inc. (NASDAQ: RGLS ), Abeona Therapeutics Inc. ... TBPH ), and Sage Therapeutics Inc. (NASDAQ: ... report by Grand View Research, global Biotech market size is expected ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... announced today the next evolution in spinal fusion, the MISquito Percutaneous Pedicle ... to the competition, SpineFrontier is focused on technique driven product solutions that ...
Breaking Biology Technology:
(Date:12/15/2016)... ... Markets has announced the addition of the "Global Military Biometrics Market ... the global military biometrics market to grow at a CAGR of 7.5% ... based on an in-depth market analysis with inputs from industry experts. The ... years. The report also includes a discussion of the key vendors operating ...
(Date:12/15/2016)... 14, 2016 "Increase in mobile transactions is ... mobile biometrics market is expected to grow from USD ... 2022, at a CAGR of 29.3% between 2016 and ... the growing demand for smart devices, government initiatives, and ... "Software component is expected to grow at a high ...
(Date:12/8/2016)... 2016  Singulex, Inc., the leader in Next Generation ... a license and supply agreement with Thermo Fisher Scientific, ... Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), a ... used to diagnose systemic bacterial infection and sepsis and ... aid in assessing the risk of critically ill patients ...
Breaking Biology News(10 mins):